UBS Group Boosts Pediatrix Medical Group (NYSE:MD) Price Target to $16.50

Pediatrix Medical Group (NYSE:MD) had its target price raised by UBS Group from $10.50 to $16.50 in a report released on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock.

MD has been the topic of a number of other research reports. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday. Jefferies Financial Group boosted their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial lifted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Up 1.5 %

Shares of NYSE MD opened at $15.36 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.58 and a debt-to-equity ratio of 0.86. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $15.52. The company’s fifty day moving average is $11.79 and its 200-day moving average is $9.50. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -5.02, a P/E/G ratio of 2.36 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up .9% on a year-over-year basis. Equities research analysts predict that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insiders Place Their Bets

In other news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the transaction, the chief financial officer now owns 175,347 shares in the company, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now directly owns 175,347 shares of the company’s stock, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,100 shares of company stock valued at $701,889 in the last three months. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MD. The Manufacturers Life Insurance Company boosted its holdings in shares of Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after acquiring an additional 1,088 shares during the period. ProShare Advisors LLC lifted its holdings in Pediatrix Medical Group by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after purchasing an additional 1,167 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares during the period. SummerHaven Investment Management LLC grew its holdings in Pediatrix Medical Group by 3.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after buying an additional 2,069 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Pediatrix Medical Group by 0.5% during the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock worth $3,196,000 after buying an additional 2,083 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.